Currax Pharmaceuticals Announces First Patient Screened into the INFORMUS Cardiovascular Outcomes Trial

January 26, 2024 01:00 AM AEDT | By EIN Presswire

Google News:

Currax Pharmaceuticals Announces First Patient Screened into the INFORMUS Cardiovascular Outcomes Trial — Image source: EIN Presswire

Recent News

Small Caps in Motion: Bubs Australia and Key ASX Penny Stocks in the A...

BlackRock Adjusts Strategy Amid Rally in Australia Equity Market

Healius (ASX:HLS) Sees IVD Growth Momentum in Australia Healthcare Lan...

Brake and Clutch Advancements Drive Auto Component Growth | Australia...

BRENTWOOD, TENNESSEE, UNITED STATES, January 25, 2024 /EINPresswire.com/ -- Currax Pharmaceuticals LLC (“Currax”) announces the first patient screened and accepted into the CONTRAVE^® INFORMUS Cardiovascular Outcomes Trial (NB-CVOT3). The initiation of this study follows the October 2023 announcement of the favorable top-line results of the completed Cardiovascular Health Outcomes Analysis (HOA) where no evidence was found of excess cardiovascular risk and there was no statistically significant difference of major adverse cardiovascular events (MACE) between CONTRAVE and the active comparator group.

“We are thrilled to be commencing the INFORMUS trial for CONTRAVE,” said Michael Kyle, M.D., Currax SVP, Chief Medical Officer. “Over the past several years, we worked diligently with regulatory agencies to develop this study protocol. To reach agreement with the FDA and initiate patients into the trial is a significant milestone for this product, these patients, and this program.”

The HOA results substantiated the cardiovascular safety profile of CONTRAVE, and the initiation of the INFORMUS trial addresses regulatory post-marketing commitments. INFORMUS will further characterize long-term cardiovascular safety for patients taking CONTRAVE. The HOA study is completed and is expected to be published later this year.

“Our clinical team successfully achieved an on-time launch of the INFORMUS trial through strong collaboration and support from the FDA,” said Currax President and CEO George Hampton. “This is an important trial for patients, as CONTRAVE is now the number one prescribed branded oral medication for the treatment of obesity.”

About the INFORMUS Trial
The INFORMUS Trial (NB-CVOT3) is a Phase IV, multi-center, prospective, randomized, pragmatic, double-blinded, placebo controlled study intended to capture cardiovascular (CV) outcomes during real-world use of naltrexone/bupropion (CONTRAVE). Randomization will occur 1:1 between CONTRAVE and placebo. The primary endpoint includes comparison of major adverse cardiovascular events (MACE) between study subjects receiving CONTRAVE and subjects receiving placebo.

About CONTRAVE/MYSIMBA
CONTRAVE, also marketed as MYSIMBA^® in the European Union and European Economic Area, is an extended-release fixed-dose combination of naltrexone and bupropion (naltrexone HCL/bupropion HCL) indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obese), or adults with a BMI of 27 kg/m2 or greater (overweight) with at least one weight-related medical problem such as high blood pressure, high cholesterol, or type 2 diabetes.

Media Contact
Hope Mueller
SVP, Strategy and Corporate Development
[email protected]

Hope Mueller
Currax Pharmaceuticals
[email protected]

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.